HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 01/03/2013 -- AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) was among the percentage gainers and moved up +6.30%. AEZS traded with volume of 1.30 million shares in the last session, as compared to average volume of 656,819 shares.
The stock showed downbeat weekly and monthly performances of +16.59% and +11.45%, respectively.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) has reported that the company has entered into a contract with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA).
AEZS’s President and Chief Executive Officer, Juergen Engel, has said that they are blessed due to the agreement with the U.S. Food and Drug Administration (FDA) which offered them with a noticeably defined development and regulatory pathway for AEterna Zentaris-108 in endometrial cancer.
Get A Free Report And Detailed Analysis On AEZS CLICK HERE
Amicus Therapeutics, Inc. (NASDAQ:FOLD), a bio pharmaceutical company, today declared that John F. Crowley, Chairman and Chief Executive Officer, will present a business summary at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2013 at 3:00 p.m. PT.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported the gain of +11.97% to $3.18 during the mid day trading session. Stock price 52 weeks high was $7.29 and 52 weeks low price was $2.47.
How Should Investors Trade FOLD After Today’s Rally? Find Out Here
Zalicus Inc (NASDAQ:ZLCS) went up +9.17% to $0.720 in mid day trading. Its fifty two week range was $0.43-$1.62. The total market capitalization remained $83.81million. ZLCS is ahead of its 52 week low 70.91% and its last month price volatility remained 5.70%. Its beta coefficient was 2.19 with a target price of $1.83. ZLCS has insider ownership of 6.77% with its institutional ownership at 12.01%. The Company’s current year earnings per share grew 1.87% while the five year EPS growth rate was 0.00%
Will ZLCS Extend Rally In The Coming Week? Find Out Here
XOMA Corporation (NASDAQ:XOMA), on January 2, 2013, showed a bullish movement of +7.92% and remained with market capitalization of 211.23 million.
The year to date performance of the stock remained positive +8.14%.
XOMA Corporation (NASDAQ:XOMA) engages in the discovery and development of antibody-based therapeutics in the U.S., Europe, as well as the Asia Pacific.
Get Free Trend Analysis on To Know More About XOMA Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)